看看醫學和病毒學專家和大廠是不是真心的時候到了。

凡是以原始spike為目標，以防止spike與ace2結合為目的的抗體都失敗了。

抗體療法已經不再提及了。

疫苗也是一樣，從根兒上選錯的標的。因此，開發出來的抗體針對的是最容易變異的部分。

這麽打下去，人是要被打廢的。歐洲對此不無擔心。很多報道已經高度質疑反複施打低效有安全隱患的疫苗的防疫方式了。

最近報道，人們終於找到病毒RBD上，曆經N代進化，而依然維持不變的區域。並已經做出抗體。

現在就看，這些專家，大廠，政府，有沒有為人之心，還是隻為了賺錢。如果是後者，很可能，新的發現會被壓製，而不會開發出針對性疫苗。因為那樣做，大廠會損失一部分利潤。

看看下一步發展吧。

https://scitechdaily.com/powerful-new-antibody-neutralizes-all-known-covid-variants/

 

What caused the SP1-77 antibody to be so broadly neutralizing? Structural studies by a collaborating team led by Bing Chen, Ph.D. and Jun Zhang, Ph.D. at Boston Children’s Hospital and the Haynes group at Duke, showed that SP1-77 works differently from current antibodies (either therapeutic antibodies or those we make in response to current vaccines).

Many of the existing antibodies work by attaching to the receptor-binding domain (RBD) of the spike in certain regions, preventing SARS-CoV-2 from binding to our cells’ ACE2 receptors, which is the initial step in infection. The SP1-77 antibody binds to the RBD as well, but in a completely different manner that does not prevent the virus from binding to ACE2 receptors.

Using a novel live-cell imaging platform described in a preprint, collaborators Alex Kreutzberger, Ph.D. and Tomas Kirchhausen, Ph.D., of Boston Children’s Hospital showed that SP1-77 prevents the virus from fusing its outer membrane with the membrane of the target cell. This thwarts the final necessary step that throws the door open to infection.

These features may inform the design of new SARS-CoV-2 vaccines. “SP1-77 binds the spike protein at a site that so far has not been mutated in any SARS-CoV-2 variant, broadly neutralizing current variants by a novel mechanism,” says Kirchhausen.